Claims for Patent: 10,114,022

Summary for Patent: 10,114,022

Title:	Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
Abstract:	The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
Inventor(s):	Gomis; Roger (Barcelona, ES), Jean-Mairet; Joel (Barcelona, ES)
Assignee:	INBIOMOTION S.L. (Barcelona, ES)
Application Number:	14/435,128
Patent Claims:	1. An in vitro method for diagnosing metastasis and/or recurrence in a subject with prostate cancer and/or an in vitro method for the prognosis of the tendency to develop metastasis and/or recurrence in a subject with prostate cancer and treating said subject to inhibit said metastasis or recurrence and/or to avoid or inhibit bone degradation, comprising: (i) quantifying the c-MAF gene expression level, copy number or amplification in a prostate tumor sample of said subject, and (ii) comparing the expression level, copy number or amplification obtained in (i) with the expression level, copy number or amplification of the c-MAF gene in a control sample, wherein an increase in the expression level, copy number or amplification of the c-MAF gene in said tumor sample with respect to the expression level, copy number or amplification of the c-MAF gene in the control sample is indicative of a positive diagnosis for metastasis and/or recurrence or a greater tendency to develop metastasis and/or recurrence, (iii) determining that the subject has an increase in the expression level, copy number or amplification of the c-MAF gene in the tumor sample with respect to the expression level, copy number or amplification of the c-MAF gene in the control sample, and (iv) administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject. 2. An in vitro method for designing a customized therapy for a subject with prostate cancer, comprising: (i) quantifying the c-MAF gene expression level, copy number or amplification in a prostate tumor sample of said subject, and (ii) comparing the expression level, copy number or amplification obtained in (i) with the expression level, copy number or amplification of the c-MAF gene in a control sample, wherein an increase in the expression level, copy number or amplification of the c-MAF gene in the tumor sample with respect to the expression level, copy number or amplification of the c-MAF gene in the control sample is indicative that said subject is susceptible to receive a therapy aiming to inhibit and/or treat metastasis of the cancer and/or an agent capable of avoiding, inhibiting or treating bone degradation, (iii) determining that the subject has an increase in the expression level, copy number or amplification of the c-MAF gene in the tumor sample with respect to the expression level, copy number or amplification of the c-MAF gene in the control sample, and (iv) administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject. 3. The method according to claim 1, wherein the metastasis is bone metastasis. 4. The method according to claim 3, wherein the bone metastasis is osteolytic metastasis. 5. The method according to claim 1 or 2, wherein the agent capable of avoiding, inhibiting and/or treating bone degradation is selected from the group consisting of: a bisphosphonate, a RANKL inhibitor, a PTH or a PTHLH inhibitor, a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, Radium-223, a cathepsin K inhibitor and combinations thereof. 6. The method according to claim 5, wherein the RANKL inhibitor is selected from the group consisting of: a RANKL specific antibody, a RANKL specific nanobody, and osteoprotegerin. 7. The method according to claim 5, wherein the RANKL inhibitor is the RANKL specific antibody denosumab, the bisphosphonate is zoledronic acid, the RANKL inhibitor is the RANKL specific nanobody ALX-0141 or the dual MET and VEGFR2 inhibitor is Cabozantinib. 8. The method according to claim 1 or 2, wherein the expression level, copy number or amplification is quantified by means of a quantitative polymerase chain reaction (PCR) or a DNA or RNA array, nucleotide hybridization technique, western blot, in situ hybridization, ELISA, immunohistochemistry or a protein array. 9. An in vitro method for diagnosing metastasis and/or recurrence in a subject with prostate cancer and/or an in vitro method for the prognosis of the tendency to develop metastasis and/or recurrence in a subject with prostate cancer and treating said subject to inhibit said metastasis or recurrence, comprising: (i) detecting a c-MAF amplification in a tumor sample of said subject relative to a reference gene copy number, wherein the amplification of the c-MAF gene is determined by means of determining the amplification of the locus 16q22-q24, wherein an amplification of the c-MAF gene with respect to said reference gene copy number is indicative of the presence of metastasis or recurrence or an increased risk of developing metastasis or recurrence, and (ii) administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject with an increase in the amplification of the c-MAF gene with respect to reference gene copy number. 10. The method according to claim 9, wherein the amplification of the c-MAF gene is determined by means of using a c-MAF gene-specific probe. 11. The method according to claim 9, wherein the reference gene copy number is that of a tumor tissue sample of prostate cancer from a subject who has not suffered metastasis. 12. The method according to claim 9, wherein the metastasis is bone metastasis. 13. The method according to claim 12, wherein the bone metastasis is osteolytic metastasis. 14. A method for inhibiting, treating or reducing bone metastasis in a subject with prostate cancer, wherein the subject has been determined to have an elevated c-MAF expression level, copy number, or amplification in a tumor sample with respect to a control sample, comprising administering an agent capable of avoiding, inhibiting and/or treating bone degradation to the subject. 15. The method according to claim 14, wherein the agent capable of avoiding, inhibiting and/or treating bone degradation is selected from the group consisting of: a bisphosphonate, a RANKL inhibitor, PTH inhibitor or a PTHLH inhibitor, a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, an EGFR inhibitor, calcitonin, Radium-223, and a cathepsin K inhibitor. 16. The method according to claim 15, wherein the RANKL inhibitor is selected from the group consisting of: a RANKL specific antibody, a RANKL specific nanobody, and osteoprotegerin. 17. The method according to claim 15, wherein the RANKL inhibitor is the RANKL specific antibody denosumab, the bisphosphonate is zoledronic acid, the RANKL inhibitor is the RANKL specific nanobody ALX-0141 or the dual MET and VEGFR2 inhibitor is Cabozantinib. 18. The method according to claim 15, wherein the bone metastasis is osteolytic metastasis. 19. A method for inhibiting, treating or reducing the risk of bone metastasis in a subject with prostate cancer, wherein the subject has been determined to have an elevated c-MAF expression level, copy number, or amplification in a tumor sample with respect to a control sample, and the c-MAF expression level, copy number, or amplification is diagnostic or prognostic of prostate cancer metastasis, comprising administering to said subject a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject with an increased risk of bone metastasis or recurrence, wherein said c-MAF inhibitor, therapy aiming to inhibit and/or treat bone metastasis, and/or agent capable of avoiding, inhibiting and/or treating bone degradation is administered in accordance with a treatment regimen determined from quantifying the expression level, amplification or copy number of c-MAF in said subject. 20. The method according to claim 10, wherein the c-MAF gene-specific probe is Vysis LSI/IGH MAF Dual Color Dual Fusion Probe. 21. An in vitro method for predicting bone metastasis or recurrence of prostate cancer in a subject suffering said cancer and treating said subject to inhibit said metastasis or recurrence and/or to avoid and/or inhibit bone degradation, comprising: (i) detecting c-MAF gene translocation in a tumor sample of said subject, wherein translocation of the c-MAF gene is indicative of an increased risk of bone metastasis or recurrence, and (ii) administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject. 22. An in vitro method for designing a customized therapy for a subject having prostate cancer with bone metastasis, wherein the subject has been determined to have an elevated c-MAF expression level, copy number, or amplification in a tumor sample with respect to a control sample, which comprises administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to the subject. 23. The method according to claim 22, wherein the agent capable of avoiding, inhibiting and/or treating bone degradation is selected from the group consisting of: a bisphosphonate, a RANKL inhibitor, a PTH or a PTHLH inhibitor, a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, Radium-223, a cathepsin K inhibitor and combinations thereof. 24. The method according to claim 23, wherein the RANKL inhibitor is selected from the group consisting of: a RANKL specific antibody, a RANKL specific nanobody, and osteoprotegerin. 25. The method according to claim 23, wherein the RANKL inhibitor is the RANKL specific antibody denosumab, the bisphosphonate is zoledronic acid, the RANKL inhibitor is the RANKL specific nanobody ALX-0141 or the dual MET and VEGFR2 inhibitor is Cabozantinib. 26. The method according to claim 14, wherein said c-MAF expression level, copy number, or amplification is measured using a means for quantifying expression that comprises a set of probes and/or primers that specifically bind and/or amplify the c-MAF gene, the 16q23 locus or the 16q22-16q24 chromosomal region. 27. The method of claim 1 or 2, wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample. 28. An in vitro method for predicting the clinical outcome of a subject with prostate cancer and further treating said subject, comprising: (i) detecting an increased expression level, copy number, amplification, translocation or gain of the c-MAF gene in a sample of said subject relative to a reference, wherein an increased expression level, copy number, amplification, translocation or gain of the c-MAF gene with respect to said reference is indicative of a poor clinical outcome, and (ii) administering a therapeutically effective amount of a c-MAF inhibitor, a therapy aiming to inhibit and/or treat bone metastasis selected from the group consisting of an mTor inhibitor, a Src kinase inhibitor, a COX-2 inhibitor, a CCR5 antagonist and/or Radium-223, and/or an agent capable of avoiding, inhibiting and/or treating bone degradation to said subject. 29. The method of any one of claim 1, 2, 9, 19, 21, 22 or 28, wherein said c-MAF inhibitor is selected from the group consisting of a c-MAF specific siRNA, a c-MAF specific antisense oligonucleotide, a c-MAF specific ribozyme, a c-MAF inhibitory antibody or nanobody, a dominant negative c-MAF variant, a compound from Table 1 or from Table 2, catalytic RNAs, DNA enzymes, inhibitory antibodies, inhibitory peptides, a c-MAF specific small molecule, a c-MAF specific antibody, a c-MAF specific antibody-like molecule, a c-MAF specific structurally constrained (cyclical) peptide, a c-MAF specific stapled peptide, or a c-MAF specific alphabody. 30. The method of any one of claim 7, 17 or 25, wherein the RANKL inhibitor is denosumab. 31. The method of any one of claim 7, 17 or 25, wherein the bisphosphonate is zoledronic acid.

Details for Patent 10,114,022

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2039-02-26
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2039-02-26